<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OncoTargets and Therapy</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6124799</article-id><article-id pub-id-type="doi">10.2147/OTT.S174103</article-id><article-id pub-id-type="publisher-id">ott-11-5303</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>E2F3 promotes cancer growth and is overexpressed through copy number variation in human melanoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Zhicai</given-names></name><xref ref-type="aff" rid="af1-ott-11-5303">1</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="af1-ott-11-5303">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Daojiang</given-names></name><xref ref-type="aff" rid="af2-ott-11-5303">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Danhua</given-names></name><xref ref-type="aff" rid="af3-ott-11-5303">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="af1-ott-11-5303">1</xref></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Fengran</given-names></name><xref ref-type="aff" rid="af1-ott-11-5303">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yanhong</given-names></name><xref ref-type="aff" rid="af4-ott-11-5303">4</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Quanyong</given-names></name><xref ref-type="aff" rid="af1-ott-11-5303">1</xref><xref ref-type="corresp" rid="c1-ott-11-5303"/></contrib></contrib-group><aff id="af1-ott-11-5303">
<label>1</label>Department of Burns and Plastic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China, <email>qyonghe@126.com</email></aff><aff id="af2-ott-11-5303">
<label>2</label>Department of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China</aff><aff id="af3-ott-11-5303">
<label>3</label>Department of Medical Laboratory, Huakang Hospital, Dazhou, Sichuan, China</aff><aff id="af4-ott-11-5303">
<label>4</label>Fujian Medical University, Fuzhou, Fujian, China</aff><author-notes><corresp id="c1-ott-11-5303">Correspondence: Quanyong He, Department of Burns and Plastic Surgery, The Third Xiangya Hospital of Central South University, Tongzipo Road, Number 172, Changsha, Hunan, China, Tel +86 133 0731 3730, Fax +86 731 8863 8888, Email <email>qyonghe@126.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>30</day><month>8</month><year>2018</year></pub-date><volume>11</volume><fpage>5303</fpage><lpage>5313</lpage><permissions><copyright-statement>&#x000a9; 2018 Feng et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Melanoma is a malignant tumor that seriously affects patients. The pathogenesis of malignant melanoma is complex, and the cell cycle is closely related to tumor progression. Based on the catalog of cancer somatic mutations, we found that overexpression of the <italic>E2F3</italic> gene ranked first in percentage increase in not only melanoma but also in all human cancer tissues. However, there are few studies on the high expression of <italic>E2F3</italic> and its carcinogenic mechanism in melanoma.</p></sec><sec><title>Methods and results</title><p>We found that <italic>E2F3</italic> showed extensive copy number amplification that was positively correlated with the expression level. Patients with high copy number had a significantly poorer prognosis. We also found that <italic>E2F3</italic> levels were significantly negatively correlated with promoter methylation. However, we showed that the <italic>E2F3</italic> promoter region is hypomethylated, and in normal cells or tumor cells, the methylation level did not correlate with expression. Finally, we knocked down the <italic>E2F3</italic> gene in melanoma cells by shRNA. Colony formation, anchorage-dependent growth, and EdU cell proliferation experiments showed a significant decrease in proliferation. Flow cytometry showed a significant increase in the G0/G1 ratio.</p></sec><sec><title>Conclusion</title><p>It can be speculated that copy number amplification and other mechanisms result in the high expression of <italic>E2F3</italic> in melanoma, which promotes tumor progression by involving the cell cycle. <italic>E2F3</italic> is a good target for the treatment of melanoma.</p></sec></abstract><abstract abstract-type="graphical"><title>Video abstract</title><p>
<media xlink:href="ott-11-5303-s.avi" xlink:type="simple" id="d35e193" position="anchor" mimetype="video"/></p></abstract><kwd-group><title>Keywords</title><kwd><italic>E2F3</italic></kwd><kwd>melanoma</kwd><kwd>mechanism</kwd><kwd>overexpression</kwd><kwd>copy number</kwd><kwd>methylation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Malignant melanoma is the most aggressive malignant tumor in the skin, and there is a clear trend toward familial clustering.<xref rid="b1-ott-11-5303" ref-type="bibr">1</xref> Of all patients who die of skin tumors, approximately 80% have malignant melanoma.<xref rid="b2-ott-11-5303" ref-type="bibr">2</xref> In 2018, the number of new cases of malignant melanoma in the US was estimated to be 91,270, and the estimated death toll was 9,320.<xref rid="b3-ott-11-5303" ref-type="bibr">3</xref></p><p>The cell cycle includes four consecutive phases, from the stationary phase (G0 phase) to the proliferative phases (G1 phase, S phase, G2 phase, and M phase) and back to the stationary phase.<xref rid="b4-ott-11-5303" ref-type="bibr">4</xref> The key to developing malignant cells is the destruction of normal cell cycle progression, especially in G1 phase. Subsequently, cell cycle-associated regulatory proteins and signal transduction pathways are altered to allow tumor cells to successfully undergo cell cycle progression, lose their ability to differentiate, and undergo malignant proliferation.<xref rid="b5-ott-11-5303" ref-type="bibr">5</xref></p><p>The mechanistic mechanism of melanoma involves the abnormal expression of multiple genes associated with cell cycle. The most important of these genes are those that play an important role in normal cell cycle activity but are overexpressed in cancer, interfering with the cell cycle and promoting the development of tumors. For example, the <italic>USP39</italic> gene is highly expressed in melanoma. Silencing <italic>USP39</italic> can inhibit the proliferation of melanoma cells in vitro and in vivo, induce G0/G1 arrest, and promote apoptosis. The <italic>STAT3</italic> gene is highly expressed in melanoma, and <italic>STAT3</italic> promotes tumor cell growth by regulating the expression of genes involved in cell survival and proliferation.<xref rid="b6-ott-11-5303" ref-type="bibr">6</xref> The <italic>cyclin E</italic> gene is also highly expressed in melanoma. <italic>Cyclin E</italic> interacts with CDK2 to form the cyclin E-CDK2 complex, which is highly expressed in both local and metastatic melanoma.<xref rid="b7-ott-11-5303" ref-type="bibr">7</xref></p><p>With the release of relevant cancer data in The Cancer Genome Atlas (TCGA) database, cancer-related research has advanced. In this study, we found in the catalog of cancer somatic mutations (TCGA database) that the <italic>E2F3</italic> gene ranked first with a 28.12% increase in expression in melanoma. However, few studies have examined the role of E2F3 in melanoma. We will explore the mechanisms that lead to elevated E2F3 in melanoma and evaluate its associated carcinogenic properties.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Bioinformatics</title><p>The catalog of cancer somatic mutations<xref rid="b8-ott-11-5303" ref-type="bibr">8</xref> is the world&#x02019;s greatest source of manual mapping of somatic mutations related to human cancer and is used to assess methylation mutations in human cancer tissues. TCGA melanoma expression level data, copy number data, and methylation data were downloaded from the TCGA website (<ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/">https://cancergenome.nih.gov/</ext-link>). The Oncomine website (<ext-link ext-link-type="uri" xlink:href="https://www.oncomine.org/resource/login.html">https://www.oncomine.org/resource/login.html</ext-link>) provided E2F3 expression analysis in the TCGA and gene expression omnibus (GEO) (accession number GSE3189 and GSE7553) databases. In addition, we have provided two supplemental tables on the data used in this article. More details about the raw data can be found in <xref ref-type="supplementary-material" rid="SD1-ott-11-5303">Tables S1</xref> and <xref ref-type="supplementary-material" rid="SD2-ott-11-5303">S2</xref>.</p></sec><sec><title>Cell culture</title><p>The human malignant melanoma cell lines SK-MEL-28, MuM-2C, A-375, and HaCaT were purchased from American Type Culture Collection, Manassas, VA, USA, and the cells were maintained according to the manufacturer&#x02019;s protocol. The cells were cultured with Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum and antibiotics (100 &#x000b5;g/mL streptomycin and 100 U/mL penicillin). All cells were cultured in a humidified environment at 37&#x000b0;C and 5% CO<sub>2</sub>. The use of the cell lines was approved by the ethics board. of Xiangya Hospital of Central South University.</p></sec><sec><title>Lentiviral production and transduction</title><p>The shRNA targeting <italic>E2F3</italic> (5&#x02032;-TTGCGTTACTTTAA GTACTAA-3&#x02032;; shR-<italic>E2F3</italic>; Thermo Fisher Scientific) was designed, and the scramble sequence (5&#x02032;-TTCTCCGAACG TGTCACGT-3&#x02032;) was used as a lentivirus negative control (NC). The human malignant melanoma cell line A375 was transfected with <italic>E2F3</italic>-shRNA and NC-shRNA viruses. The transfection efficiency of the recombinant lentivirus was tested by fluorescence microscopy (Olympus Corporation, Tokyo, Japan), and RT-PCR was used to assess the efficiency of knockdown.</p></sec><sec><title>RNA purification and reverse transcription PCR</title><p>Total RNA was extracted using TRIZOL reagent (Thermo Fisher Scientific). The reverse transcription reaction was performed using a ReverTra Ace qPCR RT Master Mix with a gDNA remover (Toyobo Co., Ltd., Osaka, Japan). The cDNA was amplified by the KODSYBR<sup>&#x000ae;</sup> qPCR Mix (Toyobo Co., Ltd.) on a LightCycler<sup>&#x000ae;</sup> 480II System (Hoffmann-La Roche, Basel, Switzerland) according to the manufacturer&#x02019;s instructions. The primer sequences for the target gene were as follows: forward primer 5&#x02032;-TATCCCTAAACCCGCTTCC-3&#x02032;, reverse primer 5&#x02032;-TTCACAAACGGTCCTTCTA-3&#x02032;.</p></sec><sec><title>DNA purification</title><p>DNA was isolated using the Easypure Genomic DNA Kit (TransGen Biotech, Beijing, People&#x02019;s Republic of China) according to the manufacturer&#x02019;s instructions. The concentration of DNA was assessed spectrophotometrically and confirmed by gel electrophoresis, and the DNA was stored at &#x02212;20&#x000b0;C. The results were normalized to <italic>glyceraldehyde-3-phosphate dehydrogenase (GAPDH)</italic> gene expression.</p></sec><sec sec-type="methods"><title>Analysis of DNA methylation</title><p>For bisulfite-polymerase chain reaction, the BSP primer was designed in MethPrimer 2.0.<xref rid="b9-ott-11-5303" ref-type="bibr">9</xref> Then, the bisulfate-modified DNA was amplified with forward and reverse primers for target genes (bisulfite sequencing or restriction PCR, BSP). The DNA fragments were purified using the Gene JET Gel Extraction Kit (Thermo Fisher Scientific) and mixed at the appropriate proportions. According to the kit instructions, the second-generation sequencing library was prepared with the VAHTSTM Turbo DNA Library Prep Kit (Vazyme Biotech Co., Ltd., Nanjing, China) for Illumina Kits (Illumina, Inc., San Diego, CA, USA), and sequencing was performed with the Illumina MiSeq high-throughput sequencing platform (Illumina, Inc.). The primers for the bisulfite sequencing were as follows: forward primer 5&#x02032;-GGATYGTTTTAGGTTAGGGAGT-3&#x02032;, reverse primer 5&#x02032;-AAAARGAAAACAACTAAATTCC-3&#x02032;.</p></sec><sec><title>Plate colony formation assay</title><p>Melanoma cells transfected with <italic>E2F3</italic>-shRNA lentivirus were used to prepare cell suspensions and counted. Two hundred cells were added to a six-well plate. The cells were further cultured in a cell incubator for 14 days, the cell culture medium was changed every 3 days, and the cell state was observed. Photographs were taken with a fluorescence microscope before the end of the experiment, and the cells were washed twice with PBS. Then, 500 &#x000b5;L of Giemsa dye was added to each well, and the cells were stained for 10&#x02013;20 minutes. The cells were washed three times with ddH<sub>2</sub>O and photographed with a digital camera.</p></sec><sec><title>Anchorage-dependent growth</title><p>The cells were suspended in 0.3% agar medium (DMEM containing 10% FBS) and plated on a 0.6% agar matrix layer at a concentration of 3.0&#x000d7;10<sup>4</sup> cells/60 mm dish. The cells were cultured in a humidified environment (5% CO<sub>2</sub>) at 37&#x000b0;C. The number of colonies that were 50 &#x000b5;m or larger were counted after 2 weeks.</p></sec><sec><title>EdU cell proliferation assay</title><p>Lentivirus-transfected melanoma cells in the logarithmic growth phase were seeded in 96-well plates. Then, 100 &#x000b5;L of 50 &#x000b5;mol/L EdU medium was added per well, and the plates were washed with PBS after 2 hours and fixed. Each well was sequentially supplemented with 100 &#x000b5;L of 1&#x000d7; Apollo staining reaction solution and 100 &#x000b5;L of 1&#x000d7; Hoechst 33,342 nuclear staining reaction solution, evaluated by EdU detection and photographed by inverted fluorescence microscopy.</p></sec><sec sec-type="methods"><title>Cell cycle analysis</title><p>Melanoma cells transfected with <italic>E2F3</italic>-shRNA lentivirus were incubated in six-well plates. When the cells reached 80% confluence, the medium was removed, the cells were suspended, and the supernatant was discarded by centrifugation. The cell pellet was washed with cold PBS. Cells were collected by centrifugation and fixed in 75% cold ethanol for 1 hour. Prior to analysis, the cells were washed with PBS again and suspended in a solution containing 10 &#x000b5;g/mL RNase A and 50 &#x000b5;g/mL propidium iodide. The cell suspension was filtered at a rate of 300 cells/second, and the cell cycle was analyzed by a FACSCalibur<sup>&#x02122;</sup> flow cytometer (BD Biosciences, San Jose, CA, USA).</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>GraphPad Prism 7 software was used to analyze the data. Methylation, copy number variation (CNV), and expression levels between normal and cancer tissues were assessed by a two-tailed unpaired Student&#x02019;s <italic>t</italic>-test, and the error bars in the figure represent the SD or SEM. Spearman&#x02019;s correlation coefficient (<italic>r</italic>) was used to determine the correlation. Receiver operator characteristic curves were constructed based on the level of <italic>E2F3</italic> gene expression. The data were considered significant at <italic>P</italic>&#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>High expression of the <italic>E2F</italic>3 gene in melanoma</title><p>Based on the TCGA data, we found that among the genes with high expression in melanoma, the <italic>E2F3</italic> gene ranked first with an increase of 28.12% (<xref ref-type="fig" rid="f1-ott-11-5303">Figure 1A and C</xref>). The <italic>E2F3</italic> gene may promote the development of melanoma. It is worth noting that E2F3-related research in the skin is extremely rare, while studies in the eye, lung, and breast are more common (<xref ref-type="fig" rid="f1-ott-11-5303">Figure 1B</xref>). We found that the lung and breast ranked second and third, respectively, while melanoma ranked first (<xref ref-type="fig" rid="f1-ott-11-5303">Figure 1C</xref>). Therefore, it is necessary to study the relationship between <italic>E2F3</italic> and melanoma. Further study found that <italic>E2F3</italic> gene expression was increased in the TCGA and GEO databases (<xref ref-type="fig" rid="f1-ott-11-5303">Figure 1D</xref>), and the ROC curve of GSE3189 revealed that <italic>E2F3</italic> can identify melanoma tissue (AUC=0.9709) (<xref ref-type="fig" rid="f1-ott-11-5303">Figure 1E</xref>). Survival analysis showed that high <italic>E2F3</italic> expression results in decreases in OS and disease-free survival (DFS) of patients (<xref ref-type="fig" rid="f1-ott-11-5303">Figure 1F and G</xref>).</p></sec><sec><title>The relationship between CNV and <italic>E2F3</italic> expression level</title><p>We sought to explore the cause of the high expression of <italic>E2F3</italic>. First, we found that <italic>E2F3</italic> showed extensive copy number amplification (CNA) and high DNA expression in solid cancers (<xref ref-type="fig" rid="f2-ott-11-5303">Figure 2A</xref>), and amplification was the main cause of high gene expression. Therefore, we hypothesized that the high expression of <italic>E2F3</italic> in melanoma was caused by CNA. The TCGA database showed that the expression <italic>E2F3</italic> level significantly increased in tissues with high copy number compared with tissues with low copy number (<xref ref-type="fig" rid="f2-ott-11-5303">Figure 2B</xref>). The expression of the <italic>E2F3</italic> gene was significantly positively correlated with CNV level (<xref ref-type="fig" rid="f2-ott-11-5303">Figure 2C</xref>), showing that CNA is one of the causes of the increase in <italic>E2F3</italic>. More importantly, we found that CNV was significantly associated with clinical prognosis, with significantly lower OS and DFS in patients with high copy number (<xref ref-type="fig" rid="f2-ott-11-5303">Figure 2D and E</xref>).</p></sec><sec><title>The relationship between DNA methylation and <italic>E2F3</italic> gene expression in the promoter region</title><p>In addition to CNA, promoter methylation is another mechanism that controls expression levels that should not be overlooked. In investigating whether high <italic>E2F3</italic> expression is regulated by methylation, we found that <italic>E2F3</italic> expression in hypermethylated tissues was obviously lower than that in tissues with low methylation by analyzing the TCGA database (<xref ref-type="fig" rid="f3-ott-11-5303">Figure 3A</xref>), and the methylation level was significantly negatively correlated with the <italic>E2F3</italic> expression level (<xref ref-type="fig" rid="f3-ott-11-5303">Figure 3B</xref>). However, we showed that methylation level did not affect OS or DFS (<xref ref-type="fig" rid="f3-ott-11-5303">Figure 3C and D</xref>). The promoter region of <italic>E2F3</italic> was heavily enriched with CpG islands (<xref ref-type="fig" rid="f3-ott-11-5303">Figure 3E</xref>), further confirming this trend. The methylation status of 19 CpG sites in the promoter region in four cell lines was analyzed by bisulfite sequencing PCR. The results showed that the promoter region was hypom-ethylated in both normal cells and malignant tumor cells and that there was no correlation between methylation and expression levels (<xref ref-type="fig" rid="f3-ott-11-5303">Figure 3F&#x02013;I</xref>; <xref ref-type="supplementary-material" rid="SD3-ott-11-5303">Tables S3</xref> and <xref ref-type="supplementary-material" rid="SD4-ott-11-5303">S4</xref>). These results suggest that methylation may not be the cause of the elevated <italic>E2F3</italic> expression.</p></sec><sec><title>Carcinogenic properties of the <italic>E2F3</italic> gene</title><p>Research about whether high <italic>E2F3</italic> expression can promote the progression of melanoma is still lacking. To solve this problem, we successfully knocked down the <italic>E2F3</italic> gene in melanoma cells. Melanoma cells that lacked the <italic>E2F3</italic> gene showed reduced proliferation in colony formation (<xref ref-type="fig" rid="f4-ott-11-5303">Figure 4A and B</xref>), anchorage-dependent growth (<xref ref-type="fig" rid="f4-ott-11-5303">Figure 4C and D</xref>), and EdU cell proliferation experiments (<xref ref-type="fig" rid="f4-ott-11-5303">Figure 4E and F</xref>). These experiments show that E2F3 can affect cell proliferation. At the same time, we found that the G0/G1 population increased significantly after <italic>E2F3</italic> gene knockdown (<xref ref-type="fig" rid="f4-ott-11-5303">Figure 4G and H</xref>), which indicates that <italic>E2F3</italic> regulates the cell cycle and promotes melanoma.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The <italic>E2F3</italic> gene is located on chromosome 6p22 and is 91.5 kb in length. E2F3 is a major member of the E2F family and plays an important role in regulating the cell cycle, proliferation, and apoptosis.<xref rid="b10-ott-11-5303" ref-type="bibr">10</xref></p><p>Feber et al found <italic>E2F3</italic> gene amplification on chromosome 6p22 in the bladder cancer cell lines TCCSUP and HT1376. Analysis showed that higher clinical stage and pathological grade of bladder cancer corresponded with a higher positive rate of <italic>E2F3</italic> expression.<xref rid="b11-ott-11-5303" ref-type="bibr">11</xref> Silven Bilke et al found that approximately 2/3 of prostate cancers showed high expression of <italic>E2F3</italic>. <italic>E2F3</italic> can be used as an independent factor to predict the OS of prostate cancer patients through multivariate analysis.<xref rid="b12-ott-11-5303" ref-type="bibr">12</xref> Ren et al found that miR-449a inhibits the expression of <italic>E2F3</italic>, which decreased when miR-449a was overexpressed in the lung cancer cell lines A549 and 95D. Another study found cell cycle arrest in G1 phase and inhibition of cell proliferation.<xref rid="b13-ott-11-5303" ref-type="bibr">13</xref> Libertini et al found that the expression of <italic>E2F3</italic> in laryngeal squamous cell carcinoma was significantly higher than that in normal nasopharyngeal mucosa (<italic>P</italic>&#x0003c;0.001), and less differentiation correlated with a higher expression level (<italic>P</italic>&#x0003c;0.05).<xref rid="b14-ott-11-5303" ref-type="bibr">14</xref> However, it is worth noting that we found that the expression level of the <italic>E2F3</italic> gene was the highest in melanoma, ranking first among all tissues, but few studies have explored this relationship. Therefore, it is necessary to conduct in-depth studies. We also confirmed that E2F3 can interfere with the cell cycle to promote the development of melanoma.</p><p>Many studies have found that CNV is an important factor affecting the prognosis of cancer patients. Specific CNVs can be used to assess prognosis.<xref rid="b15-ott-11-5303" ref-type="bibr">15</xref> A meta-analysis showed that <italic>MET</italic> gene amplification is inversely related to the OS of non-small-cell lung cancer patients and increases the risk of death.<xref rid="b16-ott-11-5303" ref-type="bibr">16</xref> Liu et al reported that lung cancer patients with four copies of the <italic>mitogen-activated protein kinase-activated protein kinase 2</italic> (<italic>MAPKAPK2</italic>) gene promoter have a shorter median survival and a 47% increased risk of death compared to those with two or three copies, which shows that the <italic>MAPKAPK2</italic> gene can be used as a genetic marker to predict the prognosis of lung cancer.<xref rid="b17-ott-11-5303" ref-type="bibr">17</xref> We confirmed that E2F3 was also regulated by this mechanism.</p><p>In addition to CNV, promoter methylation has been shown to affect gene expression in numerous studies. For example, Kim et al found that hypomethylation of the <italic>NAT1</italic> gene may increase the transcriptional activation of breast cancer genes. Therefore, the hypomethylated <italic>NAT1</italic> gene plays an important role in the development of breast cancer.<xref rid="b18-ott-11-5303" ref-type="bibr">18</xref> Other related studies include those on FGFR (sarcoma),<xref rid="b19-ott-11-5303" ref-type="bibr">19</xref> PRAME (leukemia),<xref rid="b20-ott-11-5303" ref-type="bibr">20</xref> and IGF2 (colorectal cancer).<xref rid="b21-ott-11-5303" ref-type="bibr">21</xref> The promoter hypermethylation of these genes is closely related to the occurrence of the corresponding tumors. In our study, we found that the expression level of the <italic>E2F3</italic> gene was negatively correlated with methylation but did not affect the prognosis of patients. Moreover, there was no correlation between the methylation and expression levels in four cell lines. It can be inferred that methylation may be one of the reasons for the high expression of <italic>E2F3</italic>, but more research needs to be done.</p><p>In summary, we discussed the mechanism of the high expression of <italic>E2F3</italic> in melanoma. Finally, we knocked down the <italic>E2F3</italic> gene with lentivirus, which significantly reduced the proliferation of melanoma cells and increased the proportion of cells in the G0 phase. Therefore, it can be speculated that E2F3 can promote cancer. However, considering the extensive and high expression of <italic>E2F3</italic>, more in-depth research is needed.</p></sec><sec sec-type="supplementary-material"><title>Supplementary materials</title><supplementary-material content-type="local-data" id="SD1-ott-11-5303"><table-wrap id="ts1-ott-11-5303" position="float"><label>Table S1</label><caption><p>GSE3189</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Samples</th><th valign="top" align="left" rowspan="1" colspan="1">Name column</th><th valign="top" align="left" rowspan="1" colspan="1">E2F3</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71671</td><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">215.25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71672</td><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">153.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71673</td><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">265.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71674</td><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">199.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71675</td><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">327.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71676</td><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">163.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71677</td><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="left" rowspan="1" colspan="1">203.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71678</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">319.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71679</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">283.85</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71680</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">369.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71681</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">225.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71682</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">199.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71683</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">270.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71684</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">295.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71685</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">304.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71686</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">326.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71687</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">290.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71688</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">306.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71689</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">372.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71690</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">184.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71691</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">365.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71692</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">369.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71693</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">294.65</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71694</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">367.75</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71695</td><td valign="top" align="left" rowspan="1" colspan="1">Nevus</td><td valign="top" align="left" rowspan="1" colspan="1">642</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71696</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">584.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71697</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">669.35</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71698</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">439.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71699</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">493.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71700</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">417.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71701</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">549.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71702</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">649.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71703</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">558.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71704</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">449.25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71705</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">689.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71706</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">713.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71707</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">786.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71708</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,071.75</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71709</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">405.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71710</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">686.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71711</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">634.85</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71712</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">464.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71713</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">624.65</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71714</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">610.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71715</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">676.65</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71716</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">810.25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71717</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">659.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71718</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">498.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71719</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">604.75</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71720</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">368.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71721</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">526.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71722</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">511.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71723</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">582.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71724</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">519.85</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71725</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">740.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71726</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">602.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71727</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">399.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71728</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">435.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71729</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">423.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71730</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">423</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71731</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">557.65</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71732</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">537.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71733</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">536.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71734</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">539.95</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71735</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">733.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71736</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">780.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71737</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">999.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71738</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">669.75</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71739</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">563.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM71740</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">490.6</td></tr></tbody></table></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD2-ott-11-5303"><table-wrap id="ts2-ott-11-5303" position="float"><label>Table S2</label><caption><p>GSE7553</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Samples</th><th valign="top" align="left" rowspan="1" colspan="1">Name column</th><th valign="top" align="left" rowspan="1" colspan="1">E2F3</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183222</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma in situ</td><td valign="top" align="left" rowspan="1" colspan="1">596.8995</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183223</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma in situ</td><td valign="top" align="left" rowspan="1" colspan="1">485.8525</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183226</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,043.514</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183227</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,065.36</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183228</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,097.4305</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183229</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,367.071</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183230</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">904.909</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183231</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">966.979</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183232</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">795.534</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183233</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,049.4855</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183252</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,675.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183253</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,161.0115</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183254</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">676.6665</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183255</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,252.875</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183256</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,091.715</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183257</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,446.735</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183273</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">763.7105</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183274</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,067.1765</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183275</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">972.223</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183276</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">984.8085</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183277</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">935.2895</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183278</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,323.74</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183279</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">757.3935</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183280</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,052.9955</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183281</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">970.099</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183282</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,097.2135</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183283</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,349.745</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183284</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">973.492</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183285</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">959.895</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183286</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">967.631</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183287</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,336.92</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183288</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">918.0085</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183289</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,649.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183290</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,127.6965</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183291</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,256.515</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183292</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,410.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183293</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,364.66</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183294</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">3,495.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183295</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">921.3215</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183296</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,392.965</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183297</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">582.005</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183298</td><td valign="top" align="left" rowspan="1" colspan="1">Metastatic melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,088.088</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183299</td><td valign="top" align="left" rowspan="1" colspan="1">Normal human epidermal melanocytes</td><td valign="top" align="left" rowspan="1" colspan="1">821.5565</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183234</td><td valign="top" align="left" rowspan="1" colspan="1">Normal skin</td><td valign="top" align="left" rowspan="1" colspan="1">289.57</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183300</td><td valign="top" align="left" rowspan="1" colspan="1">Normal skin</td><td valign="top" align="left" rowspan="1" colspan="1">554.652</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183301</td><td valign="top" align="left" rowspan="1" colspan="1">Normal skin</td><td valign="top" align="left" rowspan="1" colspan="1">360.1345</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183302</td><td valign="top" align="left" rowspan="1" colspan="1">Normal skin</td><td valign="top" align="left" rowspan="1" colspan="1">359.8905</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183224</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">454.667</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183225</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">472.3105</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183235</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">2,032.71</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183258</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">3,043.785</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183259</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,404.6755</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183260</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,513.8725</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183261</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,540.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183262</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">797.319</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183263</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,008.3395</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183264</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">733.7925</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183265</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,466.6135</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183266</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">838.3575</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183303</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">1,035.0555</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSM183304</td><td valign="top" align="left" rowspan="1" colspan="1">Primary melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">612.168</td></tr></tbody></table></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD3-ott-11-5303"><table-wrap id="ts3-ott-11-5303" position="float"><label>Table S3</label><caption><p>E2F3 gene relative expression of by PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Cell name</th><th valign="top" align="left" rowspan="1" colspan="1">GAPDH</th><th valign="top" align="left" rowspan="1" colspan="1">E2F3</th><th valign="top" align="left" rowspan="1" colspan="1">&#x00394;Ct</th></tr></thead><tbody><tr><td rowspan="3" valign="top" align="left" colspan="1">SK-MEL-28</td><td valign="top" align="left" rowspan="1" colspan="1">13.07</td><td valign="top" align="left" rowspan="1" colspan="1">22.12</td><td valign="top" align="left" rowspan="1" colspan="1">9.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.8</td><td valign="top" align="left" rowspan="1" colspan="1">22.11</td><td valign="top" align="left" rowspan="1" colspan="1">9.31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.93</td><td valign="top" align="left" rowspan="1" colspan="1">22.15</td><td valign="top" align="left" rowspan="1" colspan="1">9.22</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">MUM-2C</td><td valign="top" align="left" rowspan="1" colspan="1">12.81</td><td valign="top" align="left" rowspan="1" colspan="1">20.85</td><td valign="top" align="left" rowspan="1" colspan="1">8.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.76</td><td valign="top" align="left" rowspan="1" colspan="1">20.97</td><td valign="top" align="left" rowspan="1" colspan="1">8.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.47</td><td valign="top" align="left" rowspan="1" colspan="1">20.91</td><td valign="top" align="left" rowspan="1" colspan="1">8.44</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">A375</td><td valign="top" align="left" rowspan="1" colspan="1">12.43</td><td valign="top" align="left" rowspan="1" colspan="1">21.7</td><td valign="top" align="left" rowspan="1" colspan="1">9.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.23</td><td valign="top" align="left" rowspan="1" colspan="1">21.75</td><td valign="top" align="left" rowspan="1" colspan="1">9.52</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.16</td><td valign="top" align="left" rowspan="1" colspan="1">21.91</td><td valign="top" align="left" rowspan="1" colspan="1">9.75</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">HaCaT</td><td valign="top" align="left" rowspan="1" colspan="1">13.35</td><td valign="top" align="left" rowspan="1" colspan="1">20.99</td><td valign="top" align="left" rowspan="1" colspan="1">7.64</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13.31</td><td valign="top" align="left" rowspan="1" colspan="1">21.25</td><td valign="top" align="left" rowspan="1" colspan="1">7.94</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13.27</td><td valign="top" align="left" rowspan="1" colspan="1">21.32</td><td valign="top" align="left" rowspan="1" colspan="1">8.05</td></tr></tbody></table></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD4-ott-11-5303"><table-wrap id="ts4-ott-11-5303" position="float"><label>Table S4</label><caption><p>E2F3 pair all sample site methylation information table</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">E2F3 pair methylation position</th><th valign="top" align="left" rowspan="1" colspan="1">SK-MEL-28</th><th valign="top" align="left" rowspan="1" colspan="1">MUM-2C</th><th valign="top" align="left" rowspan="1" colspan="1">A-375</th><th valign="top" align="left" rowspan="1" colspan="1">HaCaT</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="left" rowspan="1" colspan="1">0.0031</td><td valign="top" align="left" rowspan="1" colspan="1">0.0041</td><td valign="top" align="left" rowspan="1" colspan="1">0.0041</td><td valign="top" align="left" rowspan="1" colspan="1">0.0033</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td><td valign="top" align="left" rowspan="1" colspan="1">0.0045</td><td valign="top" align="left" rowspan="1" colspan="1">0.0037</td><td valign="top" align="left" rowspan="1" colspan="1">0.0043</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">65</td><td valign="top" align="left" rowspan="1" colspan="1">0.0038</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.0029</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">75</td><td valign="top" align="left" rowspan="1" colspan="1">0.0041</td><td valign="top" align="left" rowspan="1" colspan="1">0.0036</td><td valign="top" align="left" rowspan="1" colspan="1">0.0029</td><td valign="top" align="left" rowspan="1" colspan="1">0.0049</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">78</td><td valign="top" align="left" rowspan="1" colspan="1">0.0033</td><td valign="top" align="left" rowspan="1" colspan="1">0.0045</td><td valign="top" align="left" rowspan="1" colspan="1">0.0026</td><td valign="top" align="left" rowspan="1" colspan="1">0.0038</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">81</td><td valign="top" align="left" rowspan="1" colspan="1">0.0035</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td><td valign="top" align="left" rowspan="1" colspan="1">0.0021</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">102</td><td valign="top" align="left" rowspan="1" colspan="1">0.0021</td><td valign="top" align="left" rowspan="1" colspan="1">0.0027</td><td valign="top" align="left" rowspan="1" colspan="1">0.0022</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">104</td><td valign="top" align="left" rowspan="1" colspan="1">0.0036</td><td valign="top" align="left" rowspan="1" colspan="1">0.0043</td><td valign="top" align="left" rowspan="1" colspan="1">0.0027</td><td valign="top" align="left" rowspan="1" colspan="1">0.0024</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">111</td><td valign="top" align="left" rowspan="1" colspan="1">0.0036</td><td valign="top" align="left" rowspan="1" colspan="1">0.0038</td><td valign="top" align="left" rowspan="1" colspan="1">0.0027</td><td valign="top" align="left" rowspan="1" colspan="1">0.0038</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">113</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.0047</td><td valign="top" align="left" rowspan="1" colspan="1">0.0035</td><td valign="top" align="left" rowspan="1" colspan="1">0.0033</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">117</td><td valign="top" align="left" rowspan="1" colspan="1">0.0033</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">123</td><td valign="top" align="left" rowspan="1" colspan="1">0.0031</td><td valign="top" align="left" rowspan="1" colspan="1">0.0024</td><td valign="top" align="left" rowspan="1" colspan="1">0.0032</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">128</td><td valign="top" align="left" rowspan="1" colspan="1">0.0051</td><td valign="top" align="left" rowspan="1" colspan="1">0.004</td><td valign="top" align="left" rowspan="1" colspan="1">0.0036</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">134</td><td valign="top" align="left" rowspan="1" colspan="1">0.0021</td><td valign="top" align="left" rowspan="1" colspan="1">0.0049</td><td valign="top" align="left" rowspan="1" colspan="1">0.0025</td><td valign="top" align="left" rowspan="1" colspan="1">0.0037</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">137</td><td valign="top" align="left" rowspan="1" colspan="1">0.0035</td><td valign="top" align="left" rowspan="1" colspan="1">0.0042</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td><td valign="top" align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">144</td><td valign="top" align="left" rowspan="1" colspan="1">0.0045</td><td valign="top" align="left" rowspan="1" colspan="1">0.0041</td><td valign="top" align="left" rowspan="1" colspan="1">0.0042</td><td valign="top" align="left" rowspan="1" colspan="1">0.0032</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">166</td><td valign="top" align="left" rowspan="1" colspan="1">0.0051</td><td valign="top" align="left" rowspan="1" colspan="1">0.0049</td><td valign="top" align="left" rowspan="1" colspan="1">0.0033</td><td valign="top" align="left" rowspan="1" colspan="1">0.0035</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">169</td><td valign="top" align="left" rowspan="1" colspan="1">0.0077</td><td valign="top" align="left" rowspan="1" colspan="1">0.0042</td><td valign="top" align="left" rowspan="1" colspan="1">0.0034</td><td valign="top" align="left" rowspan="1" colspan="1">0.0029</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">174</td><td valign="top" align="left" rowspan="1" colspan="1">0.0031</td><td valign="top" align="left" rowspan="1" colspan="1">0.0043</td><td valign="top" align="left" rowspan="1" colspan="1">0.0034</td><td valign="top" align="left" rowspan="1" colspan="1">0.0035</td></tr></tbody></table></table-wrap></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the Zensure Leader Plan of the Third Xiangya Hospital of Central South University (grant number 20170302).</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ott-11-5303"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastrelli</surname><given-names>M</given-names></name><name><surname>Tropea</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>CR</given-names></name><name><surname>Alaibac</surname><given-names>M</given-names></name></person-group><article-title>Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification</article-title><source>In Vivo</source><year>2014</year><volume>28</volume><issue>6</issue><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">25398793</pub-id></element-citation></ref><ref id="b2-ott-11-5303"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotter</surname><given-names>SC</given-names></name><name><surname>Sroa</surname><given-names>N</given-names></name><name><surname>Winkelmann</surname><given-names>RR</given-names></name><name><surname>Olencki</surname><given-names>T</given-names></name><name><surname>Bechtel</surname><given-names>M</given-names></name></person-group><article-title>A Global Review of Melanoma Follow-up Guidelines</article-title><source>J Clin Aesthet Dermatol</source><year>2013</year><volume>6</volume><issue>9</issue><fpage>18</fpage><lpage>26</lpage></element-citation></ref><ref id="b3-ott-11-5303"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2018</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><issue>1</issue><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">29313949</pub-id></element-citation></ref><ref id="b4-ott-11-5303"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norbury</surname><given-names>C</given-names></name><name><surname>Nurse</surname><given-names>P</given-names></name></person-group><article-title>Animal cell cycles and their control</article-title><source>Annu Rev Biochem</source><year>1992</year><volume>61</volume><fpage>441</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">1497317</pub-id></element-citation></ref><ref id="b5-ott-11-5303"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeijmakers</surname><given-names>JH</given-names></name></person-group><article-title>Genome maintenance mechanisms for preventing cancer</article-title><source>Nature</source><year>2001</year><volume>411</volume><issue>6835</issue><fpage>366</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">11357144</pub-id></element-citation></ref><ref id="b6-ott-11-5303"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortylewski</surname><given-names>M</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Targeting STAT3 affects melanoma on multiple fronts</article-title><source>Cancer Metastasis Rev</source><year>2005</year><volume>24</volume><issue>2</issue><fpage>315</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">15986140</pub-id></element-citation></ref><ref id="b7-ott-11-5303"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgieva</surname><given-names>J</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name></person-group><article-title>Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions</article-title><source>J Clin Pathol</source><year>2001</year><volume>54</volume><issue>3</issue><fpage>229</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">11253137</pub-id></element-citation></ref><ref id="b8-ott-11-5303"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>SA</given-names></name><name><surname>Beare</surname><given-names>D</given-names></name><name><surname>Boutselakis</surname><given-names>H</given-names></name><etal/></person-group><article-title>COSMIC: somatic cancer genetics at high-resolution</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>D1</issue><fpage>D777</fpage><lpage>D783</lpage><pub-id pub-id-type="pmid">27899578</pub-id></element-citation></ref><ref id="b9-ott-11-5303"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>LC</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>MethPrimer: designing primers for methylation PCRs</article-title><source>Bioinformatics</source><year>2002</year><volume>18</volume><issue>11</issue><fpage>1427</fpage><lpage>1431</lpage><pub-id pub-id-type="pmid">12424112</pub-id></element-citation></ref><ref id="b10-ott-11-5303"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>WO</given-names></name><name><surname>Tsch&#x000f6;p</surname><given-names>K</given-names></name><name><surname>Herr</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>JY</given-names></name><name><surname>Dyson</surname><given-names>NJ</given-names></name></person-group><article-title>Pumilio facilitates miRNA regulation of the E2F3 oncogene</article-title><source>Genes Dev</source><year>2012</year><volume>26</volume><issue>4</issue><fpage>356</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">22345517</pub-id></element-citation></ref><ref id="b11-ott-11-5303"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feber</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Goodwin</surname><given-names>G</given-names></name><etal/></person-group><article-title>Amplification and overexpression of E2F3 in human bladder cancer</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><issue>8</issue><fpage>1627</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">14716298</pub-id></element-citation></ref><ref id="b12-ott-11-5303"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilke</surname><given-names>S</given-names></name><name><surname>Schwentner</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer</article-title><source>Genome Res</source><year>2013</year><volume>23</volume><issue>11</issue><fpage>1797</fpage><lpage>1809</lpage><pub-id pub-id-type="pmid">23940108</pub-id></element-citation></ref><ref id="b13-ott-11-5303"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>XS</given-names></name><name><surname>Yin</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells</article-title><source>Cancer Lett</source><year>2014</year><volume>344</volume><issue>2</issue><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">24211326</pub-id></element-citation></ref><ref id="b14-ott-11-5303"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libertini</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Al-Bataina</surname><given-names>B</given-names></name><etal/></person-group><article-title>The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells</article-title><source>Prostate</source><year>2012</year><volume>72</volume><issue>6</issue><fpage>649</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">21837779</pub-id></element-citation></ref><ref id="b15-ott-11-5303"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaran</surname><given-names>M</given-names></name><name><surname>Cass</surname><given-names>CE</given-names></name><name><surname>Graham</surname><given-names>K</given-names></name><etal/></person-group><article-title>Germline copy number variations are associated with breast cancer risk and prognosis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>14621</fpage><pub-id pub-id-type="pmid">29116104</pub-id></element-citation></ref><ref id="b16-ott-11-5303"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group><article-title>The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>35770</fpage><pub-id pub-id-type="pmid">27786238</pub-id></element-citation></ref><ref id="b17-ott-11-5303"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group><article-title>A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer</article-title><source>Am J Hum Genet</source><year>2012</year><volume>91</volume><issue>2</issue><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">22883146</pub-id></element-citation></ref><ref id="b18-ott-11-5303"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kang</surname><given-names>HS</given-names></name><name><surname>Chang</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer</article-title><source>Oncol Rep</source><year>2008</year><volume>19</volume><issue>3</issue><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">18288399</pub-id></element-citation></ref><ref id="b19-ott-11-5303"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>M</given-names></name><name><surname>Meller</surname><given-names>I</given-names></name><name><surname>Orr-Urtreger</surname><given-names>A</given-names></name></person-group><article-title>FGFR1 overexpression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5&#x02032; CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes</article-title><source>Genes Chromosomes Cancer</source><year>2007</year><volume>46</volume><issue>11</issue><fpage>1028</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">17696196</pub-id></element-citation></ref><ref id="b20-ott-11-5303"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman-Gomez</surname><given-names>J</given-names></name><name><surname>Jimenez-Velasco</surname><given-names>A</given-names></name><name><surname>Castillejo</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia</article-title><source>Blood</source><year>2004</year><volume>104</volume><issue>8</issue><fpage>2492</fpage><lpage>2498</lpage><pub-id pub-id-type="pmid">15198948</pub-id></element-citation></ref><ref id="b21-ott-11-5303"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Onyango</surname><given-names>P</given-names></name><name><surname>Brandenburg</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Feinberg</surname><given-names>AP</given-names></name></person-group><article-title>Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><issue>22</issue><fpage>6442</fpage><lpage>6446</lpage><pub-id pub-id-type="pmid">12438232</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ott-11-5303" position="float"><label>Figure 1</label><caption><p>High expression of the <italic>E2F3</italic> gene in melanoma and its influence on prognosis.</p><p><bold>Notes:</bold> (<bold>A</bold>) A &#x0201c;Mutation Matrix&#x0201d; plot between genes and samples of melanoma tissue that contains 20 top ranked genes (rows) and TCGA samples (columns) with each box representing a Gene-Sample combination. The <italic>E2F3</italic> gene ranked as the top melanoma-related gene. (<bold>B</bold>) E2F3 has been studied in many tissues, including eye, lung, and breast, but studies of the skin are extremely rare. (<bold>C</bold>) The overexpression percentage (%) is represented as a histogram across different primary tissue types, and the overexpression percentage of the <italic>E2F3</italic> gene in melanoma is the highest. (<bold>D</bold>) The <italic>E2F3</italic> gene shows an increased expression level in melanoma tissues compared with normal tissues. The left was derived from the TCGA database, and the right was from the GSE3189 (more details can be found at <ext-link ext-link-type="uri" xlink:href="https://www.oncomine.org/">https://www.oncomine.org/</ext-link>). (<bold>E</bold>) The ROC curve of GSE3189. (<bold>F</bold>) The overexpression of the <italic>E2F3</italic> gene affected the OS of 454 melanoma patients. (<bold>G</bold>) The overexpression of the <italic>E2F3</italic> gene affected the DFS (disease free since initial treatment) of 398 melanoma patients.</p><p><bold>Abbreviations:</bold> CNV, copy number variation; DFS, disease-free survival; NRD, no related data; OS, overall survival; SKCM, skin cutaneous melanoma; TCGA, The Cancer Genome Atlas.</p></caption><graphic xlink:href="ott-11-5303Fig1"/></fig><fig id="f2-ott-11-5303" position="float"><label>Figure 2</label><caption><p>Copy number variation results in the high expression of the <italic>E2F3</italic> gene and affects prognosis.</p><p><bold>Notes:</bold> (<bold>A</bold>) COSMIC shows that E2F3 variations in solid cancer are dominated by CNV gains and overexpression. (<bold>B</bold>) The <italic>E2F3</italic> gene shows an increased expression level in patients with high E2F3 copy number (unpaired <italic>t</italic>-test, *<italic>P</italic>&#x0003c;0.0001). (<bold>C</bold>) The expression of the <italic>E2F3</italic> gene is significantly positively correlated with the CNV level. (<bold>D</bold>) The copy number of the <italic>E2F3</italic> gene affects the OS of 357 melanoma patients. (<bold>E</bold>) The copy number of the <italic>E2F3</italic> gene affects the DFS of 315 melanoma patients.</p><p><bold>Abbreviations:</bold> CNV, copy number variation; COSMIC, catalog of cancer somatic mutations; DFS, disease-free survival; OS, overall survival.</p></caption><graphic xlink:href="ott-11-5303Fig2"/></fig><fig id="f3-ott-11-5303" position="float"><label>Figure 3</label><caption><p>DNA methylation does not result in the high expression of the <italic>E2F3</italic> gene or affect prognosis.</p><p><bold>Notes:</bold> (<bold>A</bold>) The <italic>E2F3</italic> gene shows an increased expression level in patients with hypomethylation. (<bold>B</bold>) The expression of the <italic>E2F3</italic> gene is significantly inversely correlated with the methylation level. (<bold>C</bold> and <bold>D</bold>) The methylation of the <italic>E2F3</italic> gene does not affect OS and DFS. (<bold>E</bold>) The promoter region of E2F3 is enriched with CpG islands (more details can be found in MethPrimer at <ext-link ext-link-type="uri" xlink:href="http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi">http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi</ext-link>). The BSP1 synthesis sequence F1R1 contains 19 CG sites. (<bold>F</bold>) Methylation of 19 CG sites in four cell lines. (<bold>G</bold>) Relative expression by PCR. (<bold>H</bold>) Methylation levels in cells. (<bold>I</bold>) Methylation and expression levels are inconsistent in the four cell lines.</p><p><bold>Abbreviations:</bold> DFS, disease-free survival; OS, overall survival.</p></caption><graphic xlink:href="ott-11-5303Fig3"/></fig><fig id="f4-ott-11-5303" position="float"><label>Figure 4</label><caption><p>Carcinogenic properties of the <italic>E2F3</italic> gene.</p><p><bold>Notes:</bold> (<bold>A</bold>) Colony formation of the cells after transient transfection with E2F3-shRNA or NC-shRNA. (<bold>B</bold>) Histogram showing colony formation in the groups. (<bold>C</bold>) Images of anchorage-dependent growth. (<bold>D</bold>) The average number of colonies decreased following <italic>E2F3</italic> gene knockdown. (<bold>E</bold>) The <italic>E2F3</italic> gene affects cell proliferation. Proliferation was assessed using an EdU cell proliferation assay kit (magnification, 100&#x000d7;). (<bold>F</bold>) The cell proliferation rate decreased following <italic>E2F3</italic> gene knockdown. (<bold>G</bold>) The cell cycle distribution in melanoma cells transfected with E2F3-shRNA or NC-shRNA. (<bold>H</bold>) Histogram showing the cell cycle distribution (%). All the results are shown as the mean &#x000b1; SEM, *<italic>P</italic>&#x0003c;0.05.</p><p><bold>Abbreviations:</bold> KD, knockdown; NC, negative control.</p></caption><graphic xlink:href="ott-11-5303Fig4"/></fig></floats-group></article>